|

Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059）） Clinical Trials

1 actively recruiting trial

Pipeline

Early 1: 1

Top Sponsors

  • The First Affiliated Hospital of Henan University of Science and Technology1

Indications

  • T2DM1
  • Diabetes1

Other1 trial

A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.